Sign in

CIK 0001677077

  • Emerging growth company

Alzamend Neuro, Inc.

Sign in to watch
Ticker
ALZN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Apr 30
Incorporated
DE
Entity type
Operating
EIN
811822909
Phone
+1 844-722-6333
Business address
480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA, GA, 30326
  1. 4 Open-market sale Director sold 20,000 shares at $2.85 ($57,086)
  2. 4 Open-market buy 10% owner bought 22,319 shares at an average $2.05 ($45,782)
  3. 4 Open-market buy 10% owner bought 19,681 shares at an average $1.92 ($37,814)
  4. 4 Open-market buy 10% owner bought 145,000 shares at $2.57 ($373,114)
  5. 4 Derivatives Options or other derivatives
  6. 4 Exercise or conversion 10% owner acquired 100,000 shares (option exercise)
  7. 4 Derivatives Options or other derivatives
  8. 4 Exercise or conversion Director acquired 47,222 shares (option exercise)
  9. 4 Exercise or conversion Director acquired 47,222 shares (option exercise)
  10. 4 Exercise or conversion Director acquired 47,222 shares (option exercise)
  11. 4 Exercise or conversion Director acquired 47,222 shares (option exercise)
  12. 4 Open-market buy 10% owner bought 5,000 shares at $2.70 ($13,492)
  13. 4 Exercise or conversion Director acquired 2,778 shares (option exercise)
  14. 4 Exercise or conversion Director acquired 2,778 shares (option exercise)
  15. 4 Exercise or conversion Director acquired 2,778 shares (option exercise)
  16. 4 Exercise or conversion Director acquired 2,778 shares (option exercise)
  17. 4 Exercise or conversion Director acquired 100,000 shares (option exercise)
  18. 4 Exercise or conversion 10% owner acquired 150,000 shares (option exercise)
  19. 4 Open-market buy 10% owner bought 6,000 shares at $2.91 ($17,430)
  20. 4 Open-market buy 10% owner bought 4,000 shares at $3.29 ($13,170)

Page 7 of 9 · 170 filings